Mitsubishi UFJ Asset Management Co. Ltd. Acquires 63,266 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Mitsubishi UFJ Asset Management boosted its Edwards Lifesciences stake by 5.4% in the fourth quarter, buying 63,266 additional shares to bring its total holdings to 1,228,567 shares worth about $104.8 million.
• Wall Street sentiment remains mostly positive, with a Moderate Buy consensus rating and an average price target of $95.65; several firms recently reiterated or raised ratings, including Barclays, Wolfe Research, TD Cowen, and Stifel.
• Edwards Lifesciences recently reported better-than-expected quarterly results, posting EPS of $0.78 on revenue of $1.65 billion, while insiders have sold shares in recent months, including notable sales by the VP and CFO.

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,228,567 shares of the medical research company's stock after purchasing an additional 63,266 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.21% of Edwards Lifesciences worth $104,834,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $25,000. Kohmann Bosshard Financial Services LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its position in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Dorato Capital Management bought a new position in Edwards Lifesciences during the 4th quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. raised its position in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on EW. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the stock a "hold" rating in a research report on Friday, April 24th. Wolfe Research raised Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price for the company in a research report on Wednesday, April 1st. Stifel Nicolaus set a $110.00 target price on Edwards Lifesciences and gave the stock a "buy" rating in a research report on Tuesday, January 20th. TD Cowen raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Friday, January 9th. Finally, Barclays reissued an "overweight" rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $95.65.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 22,680 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,704,682.56. This trade represents a 51.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 88,096 shares of company stock worth $7,288,799. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $82.75 on Friday. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $47.71 billion, a P/E ratio of 44.01, a PEG ratio of 2.09 and a beta of 0.87. The stock's 50 day moving average is $82.16 and its 200 day moving average is $82.74. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the business posted $0.64 EPS. The company's revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.